Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNESP |
Texto Completo: | http://dx.doi.org/10.1111/jvim.15706 http://hdl.handle.net/11449/195160 |
Resumo: | Background There is no widely accepted standard medical treatment for apocrine gland anal sac adenocarcinoma (AGASACA) in dogs. Targeted agents such as toceranib may be effective in treatment of AGASACA, but the number of clinical reports investigating its efficacy is limited. Hypothesis/Aim To evaluate the efficacy of toceranib treatment of AGASACA in dogs, and to assess prognostic factors in the study population. Our hypothesis was that toceranib would provide a clinical benefit in the treatment of dogs with AGASACA. Animals Thirty-six client-owned dogs with either a cytologic or histologic diagnosis of AGASACA that were treated with toceranib alone or in combination with surgery, nonconcurrent chemotherapy or both. Methods Retrospective study. Result The median progression-free survival (PFS) and overall survival time (OST) for the study population was 313 days and 827 days, respectively. A clinical benefit from toceranib treatment was observed in 69% of dogs, with 20.7% of dogs experiencing partial response and 48.3% of dogs experiencing stable disease. Dogs that responded to toceranib treatment had significantly prolonged PFS and OST. Hypercalcemia was a negative prognostic factor for clinical outcomes. Conclusions Toceranib is effective in the treatment of AGASACA in dogs. Prospective, controlled clinical trials are needed to determine the efficacy of toceranib in comparison to other treatment protocols for dogs with AGASACA. |
id |
UNSP_eae88e3c75b4b3b7775ccb7111f5d7ef |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/195160 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogsAGASACAcanineOSTPFSBackground There is no widely accepted standard medical treatment for apocrine gland anal sac adenocarcinoma (AGASACA) in dogs. Targeted agents such as toceranib may be effective in treatment of AGASACA, but the number of clinical reports investigating its efficacy is limited. Hypothesis/Aim To evaluate the efficacy of toceranib treatment of AGASACA in dogs, and to assess prognostic factors in the study population. Our hypothesis was that toceranib would provide a clinical benefit in the treatment of dogs with AGASACA. Animals Thirty-six client-owned dogs with either a cytologic or histologic diagnosis of AGASACA that were treated with toceranib alone or in combination with surgery, nonconcurrent chemotherapy or both. Methods Retrospective study. Result The median progression-free survival (PFS) and overall survival time (OST) for the study population was 313 days and 827 days, respectively. A clinical benefit from toceranib treatment was observed in 69% of dogs, with 20.7% of dogs experiencing partial response and 48.3% of dogs experiencing stable disease. Dogs that responded to toceranib treatment had significantly prolonged PFS and OST. Hypercalcemia was a negative prognostic factor for clinical outcomes. Conclusions Toceranib is effective in the treatment of AGASACA in dogs. Prospective, controlled clinical trials are needed to determine the efficacy of toceranib in comparison to other treatment protocols for dogs with AGASACA.National Institutes of HealthUniversity of Wisconsin-MadisonUniv Wisconsin, Sch Vet Med, Dept Med Sci, 2015 Linden Dr, Madison, WI 53706 USAUniv Wisconsin, Anim Sci, Madison, WI 53706 USAUniv Estadual Paulista, Campus Jaboticabal, Jaboticabal, SP, BrazilUniv Wisconsin, Carbone Canc Ctr, Madison, WI 53706 USAUniv Estadual Paulista, Campus Jaboticabal, Jaboticabal, SP, BrazilNational Institutes of Health: K01OD020153-01A1Wiley-BlackwellUniv WisconsinUniversidade Estadual Paulista (Unesp)Heaton, Caitlin M.Fernandes, Arthur F. A.Jark, Paulo C. [UNESP]Pan, Xuan2020-12-10T17:06:36Z2020-12-10T17:06:36Z2020-01-24info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article873-881http://dx.doi.org/10.1111/jvim.15706Journal Of Veterinary Internal Medicine. Hoboken: Wiley, v. 34, n. 2, p. 873-881, 2020.0891-6640http://hdl.handle.net/11449/19516010.1111/jvim.15706WOS:000508986600001Web of Sciencereponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengJournal Of Veterinary Internal Medicineinfo:eu-repo/semantics/openAccess2021-10-22T20:28:54Zoai:repositorio.unesp.br:11449/195160Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462021-10-22T20:28:54Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs |
title |
Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs |
spellingShingle |
Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs Heaton, Caitlin M. AGASACA canine OST PFS |
title_short |
Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs |
title_full |
Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs |
title_fullStr |
Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs |
title_full_unstemmed |
Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs |
title_sort |
Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs |
author |
Heaton, Caitlin M. |
author_facet |
Heaton, Caitlin M. Fernandes, Arthur F. A. Jark, Paulo C. [UNESP] Pan, Xuan |
author_role |
author |
author2 |
Fernandes, Arthur F. A. Jark, Paulo C. [UNESP] Pan, Xuan |
author2_role |
author author author |
dc.contributor.none.fl_str_mv |
Univ Wisconsin Universidade Estadual Paulista (Unesp) |
dc.contributor.author.fl_str_mv |
Heaton, Caitlin M. Fernandes, Arthur F. A. Jark, Paulo C. [UNESP] Pan, Xuan |
dc.subject.por.fl_str_mv |
AGASACA canine OST PFS |
topic |
AGASACA canine OST PFS |
description |
Background There is no widely accepted standard medical treatment for apocrine gland anal sac adenocarcinoma (AGASACA) in dogs. Targeted agents such as toceranib may be effective in treatment of AGASACA, but the number of clinical reports investigating its efficacy is limited. Hypothesis/Aim To evaluate the efficacy of toceranib treatment of AGASACA in dogs, and to assess prognostic factors in the study population. Our hypothesis was that toceranib would provide a clinical benefit in the treatment of dogs with AGASACA. Animals Thirty-six client-owned dogs with either a cytologic or histologic diagnosis of AGASACA that were treated with toceranib alone or in combination with surgery, nonconcurrent chemotherapy or both. Methods Retrospective study. Result The median progression-free survival (PFS) and overall survival time (OST) for the study population was 313 days and 827 days, respectively. A clinical benefit from toceranib treatment was observed in 69% of dogs, with 20.7% of dogs experiencing partial response and 48.3% of dogs experiencing stable disease. Dogs that responded to toceranib treatment had significantly prolonged PFS and OST. Hypercalcemia was a negative prognostic factor for clinical outcomes. Conclusions Toceranib is effective in the treatment of AGASACA in dogs. Prospective, controlled clinical trials are needed to determine the efficacy of toceranib in comparison to other treatment protocols for dogs with AGASACA. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-12-10T17:06:36Z 2020-12-10T17:06:36Z 2020-01-24 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1111/jvim.15706 Journal Of Veterinary Internal Medicine. Hoboken: Wiley, v. 34, n. 2, p. 873-881, 2020. 0891-6640 http://hdl.handle.net/11449/195160 10.1111/jvim.15706 WOS:000508986600001 |
url |
http://dx.doi.org/10.1111/jvim.15706 http://hdl.handle.net/11449/195160 |
identifier_str_mv |
Journal Of Veterinary Internal Medicine. Hoboken: Wiley, v. 34, n. 2, p. 873-881, 2020. 0891-6640 10.1111/jvim.15706 WOS:000508986600001 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Journal Of Veterinary Internal Medicine |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
873-881 |
dc.publisher.none.fl_str_mv |
Wiley-Blackwell |
publisher.none.fl_str_mv |
Wiley-Blackwell |
dc.source.none.fl_str_mv |
Web of Science reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
|
_version_ |
1803650247540342784 |